Skip to main content
. 2024 Feb 7;11(1):e001113. doi: 10.1136/lupus-2023-001113

Table 4.

Composite endpoint analysis

CLASI-50 SRI-4 BICLA
Placebo RSLV-132 Placebo RSLV-132 Placebo RSLV-132
All participants
(N=65)
25% 36% 35% 28% 20% 26%
Baseline CLASI ≥21
(N=30)
25% 39% 8% 39% 8% 28%
Baseline SLEDAI ≥9
(N=22)
11% 31% 44% 62% 11% 23%

BICLA, British Isles Lupus Assessment Group-based Composite Lupus Assessment; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SRI-4, SLE Responder Index 4.